|
Match
|
Document |
Document Title |
|
|
6726928 |
Process for preparing solid dosage forms for unpalatable pharmaceuticals
A process for the preparation of a rapidly disintegrating dosage form a pharmaceutically active substance which has an unacceptable taste wherein there is formed a solution or a suspension in a...
|
|
|
6726931 |
Process for preparing oral sustained-release formulation of felodipine
The present invention relates to a process for producing an oral sustained-release pharmaceutical composition of felodipine. The process includes mixing together felodipine with at least an ionic...
|
|
|
6723341 |
Antibiotic product, use and formulation thereof
An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the antibiotic product being reached in less than about twelve...
|
|
|
6723737 |
Methods, pharmaceutical and therapeutic compostions for administering adenosine
The invention discloses methods for the chronic administration of adenosine, which contrary to the acute delivery of the drug by injection or infusion, acts in desensitizing adenosine receptors...
|
|
|
6723346 |
Process for preparing spray granules containing riboflavin
The invention is concerned with a novel process for the manufacture of flowable, non-dusty, binder-free riboflavin granulates by subjecting an aqueous suspension of riboflavin crystals of crystal...
|
|
|
6720004 |
Controlled release formulation of divalproex sodium
A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits...
|
|
|
6720003 |
Serotonin reuptake inhibitor formulations
A process for preparing amorphous paroxetine hydrochloride or sertraline hydrochloride is provided, which comprises preparing a solution in which paroxetine hydrochloride or sertraline...
|
|
|
6716453 |
Method for increasing the active loading of compressible composition forms
A process for increasing the percentage of active ingredient relative to non-active excipient in a compressible formulation, and also for reducing tablet size, by excluding an amount of the...
|
|
|
6716884 |
Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
A pharmaceutical composition for the administration of phloroglucinol includes phloroglucinol in combination with a buffer system capable of buffering the composition when placed in an aqueous...
|
|
|
6713089 |
Quick release pharmaceutical compositions of drug substances
The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of an active substance (a...
|
|
|
6709670 |
Aminoethanesulfonic acid-containing preparations
Preparations to be applied to the oral or nasal cavity which contain aminoethanesulfonic acid and a mucosal stimulant. When these preparations are applied to the oral or nasal cavity,...
|
|
|
6710083 |
Method of treating palmar and plantar fibromatosis
A method of treating palmar and plantar fibromatosis is disclosed. The method includes administering to a patient of a therapeutically effective amount of a composition comprising 13-cis-retinoic...
|
|
|
6709676 |
Extended release oral dosage composition
A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and...
|
|
|
6709669 |
Fast-dispersing dosage forms containing fish gelatin
The invention disclosed herein relates to a pharmaceutical composition comprising a carrier and an active ingredient, wherein the carrier is fish gelatin and the composition is a fast-dispersing...
|
|
|
6706695 |
Antilipemic formulation
An antilipemic composition, particularly to achieve a lowering of cholesterol levels comprises a biocompatible anionic polysaccharide material containing non-sulphated glucuronic acid.
|
|
|
6706284 |
Bitterness-reduced oral pharmaceutical composition
The invention relates to an oral pharmaceutical composition which has excellent drug release-controlling ability in the mouth even 5 to 10 minutes after its administration and also has excellent...
|
|
|
6706285 |
Enteric coated formulation of a benzimidazole derivative and method for preparation thereof
Disclosed are an enteric coated formulation of a benzimidazole derivative comprising a core and a film of an enteric coating agent on the surface thereof, the core containing a complex of the...
|
|
|
6706276 |
Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
Antimicrobial and contraceptive compositions and methods which prevent and/or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and/or...
|
|
|
6703361 |
Method of treating or preventing Type 1 diabetes by oral administration of insulin
Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of...
|
|
|
6702803 |
Multi-step drug dosage forms
Controlled release, multi-step drug dosage forms comprising a plurality of dose units and a plurality of separators that control release of drug from the dose units. In one embodiment, a dose unit...
|
|
|
6703045 |
Composition and method for maintaining blood glucose level
A composition useful for reducing serum glucose levels by an oral controlled release system and a method for treating diabetes in a human being by controlling the blood glucose level (BGL) and...
|
|
|
6699495 |
Methods for treating multiple sclerosis employing desmethylselegiline
Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for...
|
|
|
6699508 |
Sustained release oral preparations of fasudil hydrochloride
An oral sustained-release preparation which contains at least one active ingredient selected from the group consisting of fasudil hydrochloride and a hydrate thereof is disclosed. A method for...
|
|
|
6699502 |
Pharmaceutical compositions for controlled release of active substances
The present invention is directed a pharmaceutical composition which can be administered orally, allowing for the controlled release of at least one active substance. The composition includes at...
|
|
|
6696091 |
Pharmaceutical composition of topiramate
The invention is directed to a pharmaceutical composition of topiramate an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage...
|
|
|
6696496 |
Low water-soluble venlafaxine salts
Low water soluble salts of venlafaxine, especially venlafaxine maleate, are provided. Such salts can provide a variety of dosage forms including hydrogel-based extended release dosage forms.
|
|
|
6696085 |
Use of an acrylic type polymer as disintegrating agent
The present invention provides for the use of a polymer of the acrylic type as a disintegration agent.
|
|
|
6696088 |
Tamper-resistant oral opioid agonist formulations
Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is...
|
|
|
6696083 |
Vitamin/nutrient dosage regimentation
The efficacy of vitamins and other nutritional agents in treating and preventing various disease states is improved by administering therapeutically effective levels of these agents on a...
|
|
|
6696084 |
Spray drying process and compositions of fenofibrate
The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention...
|
|
|
6696087 |
Phosphate-binding polymer preparation technical field
A tablet containing a phosphate-binding polymer, which has an average particle size of 400 μm or less, contains particles of 500 μm or less in particle size at a ratio of 90% or more and has a...
|
|
|
6692767 |
Solid solution beadlet
Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent which in admixture form a solid solution at room...
|
|
|
6693208 |
Compounds and compositions for delivering active agents
Amino acid derivative as carrier compounds and compositions which are useful in the delivery of active agents are provided. The active agents can be a peptide, mucopolysaccharide, carbohydrate, or...
|
|
|
6692769 |
Sustained-release particles
The present invention discloses sustained release particles having a mean particle size of 300 μm, or less, comprising a drug-containing core substance coated with a mixed coating of a hydrophobic...
|
|
|
6689387 |
Phytochemicals for treatment of mastalgia and endometriosis
New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3′diindolylmethane...
|
|
|
6689385 |
Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the...
|
|
|
6689386 |
Sustained release matrix for high-dose insoluble drugs
Sustained release dosage forms of high dose insoluble drugs such as ibuprofen and methods for their manufacture are disclosed.
|
|
|
6689384 |
Stable pergolide mesylate and process for making same
A formulation and a method for manufacturing pergolide mesylate is disclosed whereby substantially stable pergolide mesylate can be manufactured without having to introduce stabilizing additives.
|
|
|
6689383 |
Chromium-histidine complexes as nutrient supplements
Chromium is an essential element which has been shown to have beneficial effects on carbohydrate and lipid metabolism. Often, dietary intake is suboptimal, and nutritional supplements may not be...
|
|
|
6689339 |
Viscous compositions containing carbon dioxide
A carbon dioxide-containing viscous composition wherein carbon dioxide bubbles are retained in an aqueous viscous composition. Use of the composition makes it possible to treat or ameliorate...
|
|
|
6689817 |
Process for preparing guaifenesin tannate
The invention pertains to a process for preparing guaifenesin tannate. The process involves the steps of mixing guaifenesin with tannic acid in the presence of water, continuing to mix the reaction...
|
|
|
6685964 |
Opioid analgesics with controlled active substance release
An orally administered preparation with controlled lease of an opioid analgesic in the form of crystals having particle size of 10 μm to 3 mm, preferably of 50 μm to 1 mm, which have at least one...
|
|
|
6683103 |
Sulfonamides for treatment of endothelin-mediated disorders
Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of...
|
|
|
6680072 |
Method for producing medicaments from plant extracts, in a solid form of administration
A dry extract is reduced in volume by compacting to produce a solid form of pharmaceutical such as a tablet or capsule containing plant extracts. The particles of compacted matter are subsequently...
|
|
|
6680069 |
Low-substituted hydroxypropyl cellulose and process for manufacturing the same
Processes for manufacturing a low-substituted hydroxypropyl cellulose are described that include dipping pulp into an alkaline solution to prepare an alkali cellulose, reacting the alkali cellulose...
|
|
|
6676967 |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
Methods for reducing flushing in individuals being treated for hyperlipidemia with nicotinic acid are disclosed. According to the methods of the present invention, flushing can be reduced in...
|
|
|
6676966 |
Extended release metformin hydrochloride formulations
An extended release formulation of metformin hydrochloride is disclosed. The metformin hydrochloride is encased within polymeric film layers providing for gradual release of the metformin...
|
|
|
6673368 |
Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients
Remedies effective for the improvement of colonic motor dysfunction such as irritable bowel syndrome, constipation or intestinal atony without causing side effects on the central nerve system....
|
|
|
6673365 |
Formulation for treatment of thromboembolism
A new pharmaceutical formulation comprising the thrombin inhibitor HOOC—CH 2 —(R)-Cgl-Aze-Pab in combination with medium chain glycerides, a process for the preparation of such a pharmaceutical...
|
|
|
6673366 |
Breast enhancement system
A breast enhancement system for reducing the symptoms of PMS and/or non-invasive breast augmentation. The composition includes an amount of saw palmetto extract, an amount of soybean extract, an...
|